Michael Farrell proposes 4,991-share sale in ResMed stock
Published on 10/08/2026 at 10:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. stock (ISIN US7611521078) was trading at EUR 201.90 at Lang & Schwarz on October 8, 2026 at 10:39 a.m. CEST, plus 0.05 percent versus the prior close of EUR 201.80. On October 7, 2026, Michael Farrell proposed selling 4,991 ResMed common shares with an aggregate market value of USD 1.13 million, according to StockTitan.
The filing involves 4,991 shares
The Form 144 notice identifies Farrell as an officer and director and records the proposed sale through Fidelity Brokerage Services on the New York Stock Exchange. It also lists a cash-paid stock option exercise for 4,991 shares dated October 7, 2026, while the filing records 144,252,306 shares outstanding.
The filing is a planned transaction rather than a new operating announcement, so its main relevance is the timing and size of the disclosed insider activity. The proposed sale value equals a small fraction of ResMed's equity value, keeping the filing separate from the company's earnings outlook.
Fiscal 2026 growth supports the backdrop
ResMed reported USD 5.7 billion of revenue for fiscal year 2026, up 10.00 percent on a reported basis from fiscal year 2025, according to the company's proxy filing with the SEC. Non-GAAP diluted earnings per share grew 17.00 percent in the same fiscal year, while the company generated more than USD 1.6 billion of free cash flow.
The combination of double-digit reported revenue growth and higher non-GAAP earnings per share gives the upcoming quarterly report a clear comparison base. The prior fiscal year provides the benchmark for investors assessing whether demand, margins and capital returns are carrying into fiscal 2027.
October 29 sets the next test
ResMed is scheduled to report first-quarter fiscal 2027 results on October 29, 2026, according to StockTitan. The date will put the October 7 filing in context by shifting attention from the proposed transaction to current revenue, earnings and cash generation.
ResMed stock holds near EUR 202
ResMed stock was trading at EUR 201.90 at Lang & Schwarz on October 8, 2026 at 10:39 a.m. CEST, compared with the EUR 201.80 prior close. The primary listing is on the NYSE under ticker RMD, and the latest USD 32.8 billion market capitalization and USD 180.27 to USD 284.05 52-week range provide the U.S. market context; StockAnalysis identifies the listing and ISIN.
The further course of trading is shown by the continuously updated real-time quote of ResMed stock.
ResMed Inc. stock facts
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: RMD
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 8, 2026, 10:39 a.m. CEST): EUR 201.90
- Change versus prior close: plus 0.05 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 201.80
- Market capitalization: USD 32.8 billion (as of October 7, 2026)
- 52-week range: USD 180.27-284.05 (as of October 7, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
